Imagen de Portada

Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Sandra A. Springer
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Addiction
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review
por: Emmert Roberts, et al.
Publicado: (2026)

Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions
por: Paolo Mannelli
Publicado: (2024)

Commentary on Stam et al .: The substantial and dynamic contribution of opioid potency to total overdose risk
por: Phillip O. Coffin
Publicado: (2024)

Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
por: Nadine Ezard, et al.
Publicado: (2025)

Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals
por: Jake R. Morgan, et al.
Publicado: (2024)

A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine
por: Charles Deng, et al.
Publicado: (2025)

Commentary on Dennett et al .: When heat and the opioid epidemic collide ‐ implications for climate‐resilient public health strategies
por: Tarik Benmarhnia
Publicado: (2025)

Commentary on Bade et al.: Threat of nitazenes and other potent synthetic opioids—Is Europe prepared? Time to respond and to learn
por: Isabelle Giraudon, et al.
Publicado: (2025)

Dose‐specific clinical outcomes in patients with opioid use disorder treated with 24–32 mg/day of buprenorphine
por: Julia D’Agata Mount, et al.
Publicado: (2024)

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
por: Gary J. Young, et al.
Publicado: (2024)

Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
por: Payel J. Roy, et al.
Publicado: (2025)

Commentary on Serre et al . : Demonstrating the next era of addiction science
por: Bryant M. Stone, et al.
Publicado: (2024)

Commentary on Getty et al .: Complementarity of harm reduction and contingency management
por: John M. Roll
Publicado: (2026)

Variations in US county‐level trends in buprenorphine use, 2018–2022
por: Taylor W. Lefler, et al.
Publicado: (2025)

Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada
por: Jenna Langlois, et al.
Publicado: (2024)

Comment on Domzaridou et al .: Recognising the complexities of co‐prescriptions and lifestyle factors in opioid agonist treatment
por: Adam Bakker, et al.
Publicado: (2024)

Commentary on Morris et al .: Shifting consumption from unhealthy to healthy commodities
por: Daniel Araya‐Ríos
Publicado: (2026)

Commentary on Jackson et al.: The role of regional tobacco control in centralised nations
por: Nathan Davies, et al.
Publicado: (2025)

Commentary on Baltes‐Flueckiger et al.: Rethinking expectations and evidence in cannabis policy
por: Sharon R. Sznitman, et al.
Publicado: (2025)

Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022
por: Rachael K. Ross, et al.
Publicado: (2024)

Extended‐release buprenorphine in pregnancy
por: Alexander Hubbell, et al.
Publicado: (2024)

Commentary on Rehm et al.: Utilizing return on investment analysis to advocate for tax increases
por: Meenakshi S. Subbaraman
Publicado: (2025)

Commentary on Nieto et al .: The heterogeneity of drug craving and considerations as a treatment endpoint
por: Justin C. Strickland, et al.
Publicado: (2026)

Distinguishing chronic disease profiles and cause of death attribution in opioid and or stimulant toxicity deaths to inform overdose prevention efforts
por: Heather Palis, et al.
Publicado: (2026)

Commentary on Andreacchi et al.: Policy responses to shifting epidemiological trends in alcohol use in Canada
por: Carolin Kilian, et al.
Publicado: (2024)

Commentary on Qeadan et al .: Leveraging opportunities to expand the substance use disorder treatment arsenal
por: Ty S. Schepis
Publicado: (2024)

Commentary on Giné et al .: The hidden face of overdose: Gender inequities along the continuum of care
por: Patrizia Carrieri, et al.
Publicado: (2025)

Commentary on Östh et al.: Sensor‐based approaches to inform alcohol interventions – beyond BAC
por: Brian Suffoletto
Publicado: (2025)

Commentary on Coelho et al .: Ecological momentary assessments may be key to the future of cannabis studies
por: Lucy Chester, et al.
Publicado: (2025)

Beyond treatment response: Injection‐site reactions as part of the extended‐release buprenorphine experience
por: Julien Cabé, et al.
Publicado: (2026)

Commentary on ter Laak et al .: The importance of drug market information and differentiating drug use patterns
por: Rory Verhagen, et al.
Publicado: (2024)

Commentary on Carrasquilla et al.: Smoking and obesity; uncovering causal mechanisms through triangulation of different methods
por: Margot P. van de Weijer, et al.
Publicado: (2024)

Commentary on Lim et al .: Real‐world e‐cigarette use under prescription‐only regulation
por: Dimitra Kale, et al.
Publicado: (2026)

Commentary on Ezard et al.: Agonist‐based medications for stimulant use disorder—Distinguishing their true colours
por: Vitor S. Tardelli, et al.
Publicado: (2025)

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling
por: Rachel Lees Thorne, et al.
Publicado: (2025)

Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder – an urgent path forward
por: Adam Bisaga
Publicado: (2025)

Commentary on Dobbie et al .: Preventing adolescent gambling‐related harm—Is a universal approach sufficient?
por: Jérémie Richard
Publicado: (2026)

Commentary on Day et al.: Systemic solutions for recovery support services in Ireland's National Drug Strategy
por: Jo‐Hanna H. Ivers
Publicado: (2025)

Commentary on Amin‐Esmaeili et al .: Non‐abstinence outcomes in stimulant clinical trials—Why deny improvement?
por: Vítor S. Tardelli
Publicado: (2024)

Commentary on Zhu et al .: Nitazenes—Tracking a moving target from linked United States databases
por: Christophe P. Stove, et al.
Publicado: (2026)